MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
9.15
-0.02
-0.22%
Closed 16:00 06/14 EDT
OPEN
9.04
PREV CLOSE
9.17
HIGH
9.23
LOW
9.00
VOLUME
673.76K
TURNOVER
0
52 WEEK HIGH
16.90
52 WEEK LOW
4.260
MARKET CAP
502.45M
P/E (TTM)
-3.9396
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ATXS last week (0603-0607)?
Weekly Report · 5d ago
Astria Therapeutics Shareholders Meeting Decisions and Elections
TipRanks · 06/06 21:12
ASTRIA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/04 20:10
Weekly Report: what happened at ATXS last week (0527-0531)?
Weekly Report · 06/03 11:07
Astria Therapeutics’ STAR-0215: A Strong Buy on Potential Market Leadership in HAE Treatment
TipRanks · 05/31 14:25
Weekly Report: what happened at ATXS last week (0520-0524)?
Weekly Report · 05/27 11:11
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Astria Therapeutics, Inc. Will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024. Astria is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases.
Barchart · 05/24 07:00
Astria Therapeutics Price Target Cut to $25.00/Share From $29.00 by Oppenheimer
Dow Jones · 05/21 12:12
More
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.

Webull offers Astria Therapeutics Inc stock information, including NASDAQ: ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.